DIAGNOSTIC SIGNIFICANCE OF IMMUNITY MARKERS IN INFLAMMATORY CARDIOMYOPATHY PATIENTS

Aim. To evaluate diagnostic significance of biomarkers for inflammatory cardiomyopathy (ICM).

Material and methods. Totally, 35 patients included with suspected inflammatory cardiomyopathy, chronic heart failure of I-III functional class (FC), decreased systolic function of the left ventricle (EF LV <40%). All patients, together with routine assessments, underwent endomyocardial biopsy (EMB). Studying bioptates, the methods were used of histology and immunohistochemistry with monoclonal antibodies to monocytes/macrophages, to T-lymphocytes (CD 45RO, CD3+, CD4+, CD8+, CD68+).

Diagnosis of ICM was set if in myocardium there were inflammatory infiltrates related to degeneration or necrosis of myocytes of non-ischemic origin, and number of leucocytes was 14 or more (including up to 4 monocytes) in 1 mm2 of specimen, and at least 7 of them should be CD3+ T-lymphocytes. According to the results, patients were selected to the groups of ICM and non-inflammatory dilation ardiomyopathy (niDCM). In all patients we evaluated the following biomarkers: immunoglobulines A, M, G, high-sensitive C-reactive protein (hsCRP), matrix metalloprotease-9 (MMP9), transforming growth factor β (TGFβ), tumor necrosis factor α, (TNFα), C3 and C4 components of complement, eosinophilic catione protein (ECP).

Results. While comparing groups ICM and niDCM by the parameters of humoral immunity, it was revealed that levels of hsCRP, C3 and C4 complement, MMP9, TGFβ were significantly higher in ICM group. In ROC analysis it was found that only hsCRP, C3 and C4 complement and MMP9 have diagnostic significance. The levels of the biomarkers mentioned, were assessed with a threshold definition for optimum sensitivity and specificity: 1,13 mg/mL, 1,2 g/L, 0,256 g/L, 680 ng/mL, respectively. Using combined biomarkers hsCRP with C3, C4 complement sensitivity reached 61%, specificity 94%; in MMP6 with C3, C4 complement — 66% and 94%, respectively.

Conclusion. Combination of hsCRP and MMP9 with C3, C4 components of complement is worthy to use in diagnostics of ICM.

1. Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme — a survey on the quality of care among patients with heart failure in Europe. Eur Heart J 2003;24:442—463. DOI: http://dx.doi.org/10.1016/S0195-668X(02)00700-5

2. Tereschenko SN, Alaeva EN, Narusov OYu et al. Prevalence and diagnosis of dilated cardiomyopathy according to Russian register. Kardiologiia 2012, 7:67-72. Russian (Терещенко С.Н., Алаева Е.Н., Нарусов О.Ю. и др. Распространенность и диагностика дилатационной кардиомиопатии по данным Российского регистра. Кардиология 2012, 7:67-72).

3. Kaye M. The Registry of the International Society for Heart and Lung Transplantation: Ninth Official Report. J Heart Lung Transplant 1992;11:599—606.

4. Caforio AL, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636–2648. DOI: http://dx.doi.org/10.1093/eurheartj/eht210

5. Mason JW, O’Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis: The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269–275. DOI: 10.1056/NEJM199508033330501

6. Felker GM, Hu W, Hare JW,et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience in 1278 patients. Medicine 1999;78:270–283.

7. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:1867–1876. DOI: 10.1001/jama.296.15.1867

8. Richardson P., McKenna W, Bristow M et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93: 841–842. DOI: https://doi.org/10.1161/01.CIR.93.5.841

9. Maisch B, Beltman, Factor S, et al. World Heart Federation consensus conferences’ definition of inflammatory cardiomyopathy(myocarditis): report from two expert committees on histology and viral cardiomyopathy. Heartbeat 1999; 4: 3-4.

10. Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, et al. A prospective

11. study of biopsy-proven myocarditis: Prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28:1326–33. DOI: http://dx.doi.org/10.1093/eurheartj/ehm076

12. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32:2616–25. DOI: http://dx.doi.org/10.1093/eurheartj/ehr165

13. Paleev NP, Paleev FN. Immunopathology of myocarditis. Kreativnaia Kardiologiia 2007; 1-2: 46-55. Russian. (Палеев Н.Р., Палеев Ф.Н. Иммунопатология миокардитов. Креативная кардиология. 2007; 1-2: 46-55).

14. Satoh M, Nakamura M, Akatsu T et al. C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 2005;7:748–754. DOI: 10.1016/j.ejheart.2004.10.018

15. Ishikawa C, Tsutamoto T, Fujii M, et al. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J 2006;70:857–863. DOI: http://doi.org/10.1253/circj.70.857

16. B. Maisch, S.Pankuweit. Standard and etiology-directed evidence-based therapies in myoarditis: state of the art and future perspectives. Springer Science+Business Media New York 2012.

17. Rubis P. The diagnostic work up of genetic and inflammmatory dilated cardiomyopathy. E-journal of Cardiology Practice. http://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-13/The-diagnostic-work-up-of-genetic-and-inflammatory-dilated-cardiomyopathy (07 Apr 2015).

18. Sampietro, ТD, Neglia A, Bionda, B et al. Inflammatory markers and serum lipids in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 96;2005;pp.1718-1720. DOI: http://dx.doi.org/10.1016/j.amjcard.2005.07.093

19. Kaneko K., Kanda T., Yamauchi Y., et al. C-reactive protein in dilated cardiomyopathy. Cardiology 1999.91:215–219. DOI: 10.1159/000006913

20. Du Clos TW. Function of C-reactive protein. Ann Med, 2000, May; 32(4):274-8.

21. Webb D.J., Muirhead G.J., Wulff M., et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol, 2000:36:25–31. DOI: http://dx.doi.org/10.1016/S0735-1097(00)00705-1

22. Fung H.L., Chong S., et al. Mechanisms for the pharmacologic interaction of organic nitrates with thiols: existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acteylcysteine.1988: J Pharmacol Exp Ther 245:524–530.

23. Guo JG. Detection of cardiac troponin and high-sensitivity C reactive protein in children with viral myocarditis. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jun;28(6):1076-7.

24. Kaya, Z., M. Afanasyeva, Y. Wang, et al. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2001;2(8):739-45. doi:10.1038/90686

25. EL Nasonov, MYu Samsonov, , LZ Aleksandrova et al. Activation of the complement system in dilated cardiomyopathy. Ter Arkh 1989;61:4:59-63. Russian (Е.Л. Насонов, М.Ю. Самсонов, Л.З. Александрова и др. Активация системы комплемента при дилатационной кардиомиопатии. Тер. архив 1989:61:№4:59-63).

26. D. Westermann, , K Savvatis, H-P. Schultheiss, C. Tschöpe. Immunomodulation and matrix metalloproteinases in viral myocarditis. Journal of molecular and cellular cardiology .V. 48, issue3, March 2010, pp.468-473. DOI: http://dx.doi.org/10.1016/j.yjmcc.2009.08.019

27. F.G. Spinale, M.L. Coker, L.J. Heung, B.R. Bond, H.R. Gunasinghe, T. Etoh, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102 (16):1944-1949. DOI: https://doi.org/10.1161/01.CIR.102.16.1944

28. RC Gomes, Fares J., de Assis Silva Gomes, et al. Matrix Metalloproteinases 2 and 9 Are Differentially Expressed in Patients with Indeterminate and Cardiac Clinical Forms of Chagas Disease. Infect Immun. Oct 2013; 81(10):3600–3608. doi: 10.1128/IAI.00153-13

29. Vanhoutte D, van Almen GC, van Aelst LN et al. Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allogaft rejection. Eur heart J.2013 Jul;34(25):1930-41. DOI: http://dx.doi.org/10.1093/eurheartj/ehs375